• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化临床试验中咯血的风险:一项回顾性队列研究。

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.

作者信息

Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume P A

机构信息

Seattle Children's Research Institute, 2001 8th Ave Ste 400, Seattle, WA 98145-5005, United States.

Seattle Children's Research Institute, 2001 8th Ave Ste 400, Seattle, WA 98145-5005, United States; Department of Biostatistics, University of Washington, Seattle, WA, United States; Department of Pediatrics, University of Washington, 4800 Sand Point Way N.E., Box 5371, Seattle, WA 98105-0371, United States.

出版信息

J Cyst Fibros. 2015 Sep;14(5):632-8. doi: 10.1016/j.jcf.2015.02.003. Epub 2015 Feb 25.

DOI:10.1016/j.jcf.2015.02.003
PMID:25725985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4549226/
Abstract

BACKGROUND

Cystic fibrosis (CF) is characterized by airway infection and inflammation resulting in respiratory complications including hemoptysis. The objectives of this study were to characterize the risk of hemoptysis attributable to underlying disease and in the presence of standard of care therapy.

METHODS

This retrospective cohort study estimated hemoptysis rates overall and by relevant risk factors utilizing adverse event data from longitudinal prospective CF clinical trials.

RESULTS

Of the 1008 participants, 73% were ≤18 years old; of 929 with available spirometry, 27% had an FEV1<70% predicted. During the average 8.2 months of follow-up, 8% experienced ≥1 hemoptysis events (95% CI: 6%, 10%). Of the 125 events, 76% were mild in severity and only 9% were serious. Hemoptysis rates were greater among adults than children, those with FEV1<70% predicted, and participants infected with P. aeruginosa but not with S. aureus.

CONCLUSIONS

Hemoptysis is a common adverse event among CF clinical trial participants, and particularly in adults with more severe lung disease. These results can be used to predict event occurrence in future clinical trials.

摘要

背景

囊性纤维化(CF)的特征是气道感染和炎症,可导致包括咯血在内的呼吸道并发症。本研究的目的是确定潜在疾病以及在标准治疗存在的情况下咯血的风险。

方法

这项回顾性队列研究利用纵向前瞻性CF临床试验的不良事件数据,总体上以及按相关风险因素估算咯血发生率。

结果

1008名参与者中,73%年龄≤18岁;929名有肺功能测定数据者中,27%的第一秒用力呼气容积(FEV1)<预测值的70%。在平均8.2个月的随访期间,8%的人经历了≥1次咯血事件(95%置信区间:6%,10%)。在125次事件中,76%为轻度,只有9%为重度。成人、FEV1<预测值的70%者以及感染铜绿假单胞菌但未感染金黄色葡萄球菌的参与者咯血发生率更高。

结论

咯血是CF临床试验参与者中常见的不良事件,尤其是在患有更严重肺部疾病的成人中。这些结果可用于预测未来临床试验中事件的发生。

相似文献

1
Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.囊性纤维化临床试验中咯血的风险:一项回顾性队列研究。
J Cyst Fibros. 2015 Sep;14(5):632-8. doi: 10.1016/j.jcf.2015.02.003. Epub 2015 Feb 25.
2
Massive hemoptysis in cystic fibrosis.囊性纤维化中的大量咯血。
Chest. 2005 Aug;128(2):729-38. doi: 10.1378/chest.128.2.729.
3
Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States.美国囊性纤维化患者咯血与肺移植或不移植的死亡风险。
Ann Am Thorac Soc. 2022 Dec;19(12):1986-1992. doi: 10.1513/AnnalsATS.202202-110OC.
4
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.囊性纤维化患者中多重耐药铜绿假单胞菌的发病率及危险因素
Chest. 2007 Aug;132(2):562-8. doi: 10.1378/chest.06-2888. Epub 2007 Jul 23.
5
Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis.铜绿假单胞菌可传播株感染与成人囊性纤维化患者的临床结局。
JAMA. 2010 Nov 17;304(19):2145-53. doi: 10.1001/jama.2010.1665.
6
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.阿奇霉素用于长期感染铜绿假单胞菌的囊性纤维化患者:一项随机对照试验。
JAMA. 2003 Oct 1;290(13):1749-56. doi: 10.1001/jama.290.13.1749.
7
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.囊性纤维化肺部治疗指南:肺部并发症:咯血和气胸。
Am J Respir Crit Care Med. 2010 Aug 1;182(3):298-306. doi: 10.1164/rccm.201002-0157OC.
8
Bronchial artery embolization in adults with cystic fibrosis: impact on the clinical course and survival.成人囊性纤维化患者的支气管动脉栓塞术:对临床病程和生存的影响。
J Vasc Interv Radiol. 2006 Jun;17(6):953-8. doi: 10.1097/01.RVI.0000222822.82659.50.
9
Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker.囊性纤维化肺病中小气道受累:常规肺功能检查作为早期和敏感的标志物。
Pediatr Pulmonol. 2013 Nov;48(11):1081-8. doi: 10.1002/ppul.22777. Epub 2013 Feb 8.
10
Pneumothorax in cystic fibrosis.囊性纤维化中的气胸
Chest. 2005 Aug;128(2):720-8. doi: 10.1378/chest.128.2.720.

引用本文的文献

1
Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.囊性纤维化患者感染的治疗干预措施:IV期试验综述
J Clin Med. 2024 Oct 30;13(21):6530. doi: 10.3390/jcm13216530.
2
Factors associated with cystic fibrosis mortality before the age of 30: retrospective analysis of a cohort in southern Brazil.与 30 岁前囊性纤维化死亡相关的因素:巴西南部队列的回顾性分析。
Braz J Med Biol Res. 2024 Aug 23;57:e13476. doi: 10.1590/1414-431X2024e13476. eCollection 2024.
3
Morphological chest CT changes in cystic fibrosis and massive hemoptysis.

本文引用的文献

1
Cystic fibrosis: management of haemoptysis.囊性纤维化:咯血的处理。
Paediatr Respir Rev. 2012 Dec;13(4):200-5. doi: 10.1016/j.prrv.2012.01.003. Epub 2012 Feb 28.
2
Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.非铜绿假单胞菌感染 CF 患儿阿奇霉素开放性标签、后续研究。
Pediatr Pulmonol. 2012 Jul;47(7):641-8. doi: 10.1002/ppul.21601. Epub 2012 Jan 3.
3
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.囊性纤维化跨膜电导调节因子增效剂治疗囊性纤维化跨膜电导调节因子 G551D 突变患者。
囊性纤维化并大咯血的胸部 CT 形态学改变。
Radiologie (Heidelb). 2024 Nov;64(Suppl 1):76-85. doi: 10.1007/s00117-024-01266-4. Epub 2024 Feb 7.
4
Bronchial artery diameter in massive hemoptysis in cystic fibrosis.支气管动脉直径在囊性纤维化大咯血中的变化。
BMC Pulm Med. 2022 Nov 17;22(1):424. doi: 10.1186/s12890-022-02233-2.
5
Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.囊性纤维化肺部并发症:过去、现在和未来:成人囊性纤维化系列。
Chest. 2021 Oct;160(4):1232-1240. doi: 10.1016/j.chest.2021.06.017. Epub 2021 Jun 17.
6
Rates of adverse and serious adverse events in children with cystic fibrosis.囊性纤维化患儿不良和严重不良事件的发生率。
J Cyst Fibros. 2021 Nov;20(6):972-977. doi: 10.1016/j.jcf.2021.02.013. Epub 2021 Mar 18.
7
Predictors of massive haemoptysis after a first episode of mild-to-moderate haemoptysis in patients with cystic fibrosis.囊性纤维化患者首次出现轻至中度咯血后大量咯血的预测因素。
ERJ Open Res. 2020 Sep 14;6(3). doi: 10.1183/23120541.00382-2020. eCollection 2020 Jul.
8
Privatisation rescues function following loss of cooperation.私有化可在合作丧失后恢复功能。
Elife. 2018 Dec 18;7:e38594. doi: 10.7554/eLife.38594.
9
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.标准化治疗肺部加重(STOP)研究:囊性纤维化肺部加重静脉内抗生素治疗开始时的观察。
J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.
N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
4
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.4种随机治疗方案用于治疗囊性纤维化患儿早期铜绿假单胞菌感染的疗效和安全性比较
Arch Pediatr Adolesc Med. 2011 Sep;165(9):847-56. doi: 10.1001/archpediatrics.2011.136.
5
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.囊性纤维化肺部治疗指南:肺部并发症:咯血和气胸。
Am J Respir Crit Care Med. 2010 Aug 1;182(3):298-306. doi: 10.1164/rccm.201002-0157OC.
6
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.阿奇霉素对非绿脓假单胞菌感染囊性纤维化患者肺功能的影响:一项随机对照试验。
JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.
7
Hemoptysis in Israeli CF patients--prevalence, treatment, and clinical characteristics.以色列囊性纤维化患者的咯血——患病率、治疗及临床特征
J Cyst Fibros. 2008 Jul;7(4):301-306. doi: 10.1016/j.jcf.2007.11.007. Epub 2008 Jan 9.
8
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.重复雾化腺相关病毒载体-囊性纤维化跨膜传导调节因子治疗囊性纤维化:一项随机安慰剂对照2B期试验
Hum Gene Ther. 2007 Aug;18(8):726-32. doi: 10.1089/hum.2007.022.
9
Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.短期和长期吸入治疗试验中囊性纤维化安慰剂受试者的呼吸道不良事件概况。
Contemp Clin Trials. 2006 Dec;27(6):561-70. doi: 10.1016/j.cct.2006.06.001. Epub 2006 Jun 9.
10
Massive hemoptysis in cystic fibrosis.囊性纤维化中的大量咯血。
Chest. 2005 Aug;128(2):729-38. doi: 10.1378/chest.128.2.729.